

August 12, 2025

SymBio Pharmaceuticals Limited  
Fuminori Yoshida  
Representative Director,  
President and Chief Executive Officer  
Noritaka Narimiya  
Executive Corporate Officer and Chief Financial Officer  
TEL: +81-3-5472-1125

**Notice Regarding the Completion of Payment for the Issue Price of the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment**

SymBio Pharmaceuticals Limited (the “Company”) hereby announces that payment of the total issue price of ¥3,300,000 for the 65th to 67th stock acquisition rights (respectively, the “65th Stock Acquisition Rights,” the “66th Stock Acquisition Rights,” and the “67th Stock Acquisition Rights”; collectively or individually, the “Stock Acquisition Rights”) issued through a third-party allotment to EVO FUND (the “EVO FUND” or the “Allottee”), as resolved at the Board of Directors meeting held on July 22, 2025, was completed on August 12, 2025.

For details regarding the issuance of the Stock Acquisition Rights, please refer to the “Notice Regarding the Issuance of the 65th to 67th Stock Acquisition Rights (with Exercise Price Adjustment Clauses) through Third-Party Allotment and the Execution of a Purchase Agreement (Commit Issue) for the 1st Unsecured Straight Bonds and Stock Acquisition Rights,” released on July 22, 2025.

<Overview of the Issuance of the Stock Acquisition Rights>

(1) Allotment Date	August 12, 2025
(2) Total Number of Stock Acquisition Rights	500,000 units 65th Stock Acquisition Rights: 200,000 units 66th Stock Acquisition Rights: 200,000 units 67th Stock Acquisition Rights: 100,000 units
(3) Issue Price	Total of ¥3,300,000 ¥8 for each unit of the 65th Stock Acquisition Rights ¥7 for each unit of the 66th Stock Acquisition Rights ¥3 for each unit of the 67th Stock Acquisition Rights
(4) Potential Shares from the Issuance	50,000,000 shares (100 shares per unit of Stock Acquisition Rights) 65th Stock Acquisition Rights: 20,000,000 shares 66th Stock Acquisition Rights: 20,000,000 shares 67th Stock Acquisition Rights: 10,000,000 shares There is no upper limit on the exercise price. The lower limit of the exercise price is set at ¥84. Even in the case where the exercise price reaches this lower limit, the total number of potential shares remains 50,000,000.
(5) Total Funds to Be Raised	¥8,353,300,000 (Note)
(6) Exercise Price and Conditions for Adjustment of	The initial exercise price is ¥168. The exercise price will first be adjusted on the second trading day (inclusive) following the allotment date (where “trading day” refers to a day on which trading is conducted on the Tokyo Stock

Exercise Price	<p>Exchange; the same applies hereinafter). Thereafter, the exercise price will be adjusted every two trading days (such two-day periods are hereinafter referred to as the “Price Determination Period”). Each date on which such an adjustment occurs is referred to individually or collectively as an “Adjustment Date.” When the exercise price is adjusted under this clause, it shall be revised on the Adjustment Date to an amount equal to 100% of the closing price of the Company’s common shares in regular trading on the Tokyo Stock Exchange on the trading day immediately preceding the Adjustment Date (the “Reference Date”; such revised price, the “Revised Exercise Price”). If no closing price is available for the Reference Date, the closing price on the most recent prior trading day shall be used. However, if the resulting Revised Exercise Price is lower than the minimum exercise price, it shall be deemed equal to the minimum exercise price. If no closing prices are available on any trading day during a given Price Determination Period, no adjustment will be made.</p> <p>In addition, if any event occurs on a Price Determination Date that triggers an adjustment as stipulated in Item 11 of the Terms and Conditions of Issuance of the Stock Acquisition Rights, the closing price on such Price Determination Date shall be adjusted in light of the relevant event.</p> <p>However, no adjustment shall be made during the period starting from one trading day (inclusive) prior to the Record Date, etc. (as defined below) through the Record Date, etc. (inclusive)—such Record Date, etc. being the date on which the exercise of Stock Acquisition Rights is restricted due to the record date for the Company’s general meeting of shareholders or procedural matters related to the Japan Securities Depository Center, Inc. (JASDEC). In such cases, the next adjustment shall occur on the second trading day (inclusive) following the Record Date, etc., and thereafter, the exercise price shall be adjusted every two trading days in accordance with Item 10 of the Terms and Conditions of Issuance of each Stock Acquisition Right.</p>
(7) Method of Offering or Allotment (Allottee)	All of the Stock Acquisition Rights will be allotted to EVO FUND through a third-party allotment.
(8) Exercise Period	From August 13, 2025 to May 15, 2028
(9) Other Terms	<p>The Company entered into a purchase agreement for the Stock Acquisition Rights (the “Purchase Agreement”) with the Allottee after the effectiveness of the securities registration statement filed under the Financial Instruments and Exchange Act, which includes: (i) the exercise commitment clause; (ii) a clause requiring the approval of the Company’s Board of Directors in the event that the Allottee seeks to transfer any of the Stock Acquisition Rights; and (iii) provisions regarding lock-up, right of first refusal, and other related matters.</p> <p>* Lock-up</p> <p>The Company shall not, without obtaining the prior written consent of EVOLUTION JAPAN SECURITIES Co., Ltd. (located at 4-1 Kioi-cho, Chiyoda-ku, Tokyo; Representative Director: Shaun Lawson) (hereinafter referred to as “EJS”)—provided, however, that if the Company requests to engage in discussions regarding such consent, EJS shall comply with such request—directly or indirectly engage in, or cause any person acting</p>

at the Company's direction to engage in, any solicitation, pledge, issuance, sale, sale agreement, grant of purchase options or rights, grant of subscription rights, loan, or any other transfer or disposition of, or any swap or other arrangement intended to transfer all or part of the economic consequences of ownership of, the Company's common shares or any securities convertible into or exchangeable for the Company's common shares, during the period beginning on the execution date of the Purchase Agreement and continuing for so long as the 1st unsecured straight bonds (the "Bonds") remain outstanding. However, the foregoing restrictions shall not apply in the following cases: (i) where the Company conducts such acts with the Allottee or its affiliates as counterparties; (ii) where the Company issues or delivers common shares by way of a stock split; (iii) where the Company allots free shares of its common stock; (iv) where the Company disposes of treasury shares pursuant to Article 194, Paragraph 3 of the Companies Act; (v) where the Company issues or delivers common shares under a restricted stock compensation plan; (vi) where the Company issues or delivers stock acquisition rights or common shares under a stock option plan; (vii) where the Company issues the Stock Acquisition Rights under this Scheme; (viii) where the Company issues or delivers common shares upon exercise of such Stock Acquisition Rights; (ix) where the Company issues or delivers common shares upon the exercise of stock acquisition rights or other similar rights that have already been disclosed as of the execution date of the Purchase Agreement; and (x) where such acts are otherwise required under applicable laws or regulations. In the event that the Company breaches this provision and receives a demand from the Allottee, the Company shall immediately pay a penalty to EJS or to a party designated by EJS.

**\*Right of First Refusal**

From the date of execution of the Purchase Agreement and for so long as the Bonds remain outstanding, in the event the Company intends to issue or deliver any shares, stock acquisition rights, or bonds with stock acquisition rights or similar securities (hereinafter referred to as the "Additional Equity Securities"; such issuance or delivery, the "Additional Issuance"), the Company shall, except where it has obtained the prior written consent of EJS, notify EJS in writing of the principal terms and conditions of the proposed Additional Issuance—such as the type, price, quantity, payment date, terms of the underwriting agreement, and the name and address of the prospective allottee, among others (the same applies hereinafter)—no later than three (3) weeks prior to the date of the meeting of the Board of Directors at which the resolution for the Additional Issuance is to be adopted.

Upon receipt of the foregoing notice, the Allottee shall notify the Company in writing, within one (1) week from (but excluding) the date of receipt of such notice, whether or not it will subscribe to the Additional Equity Securities on the terms and conditions stated in the notice. If the Allottee notifies the Company that it will subscribe on the same terms and

	<p>conditions (such notice, the “Acceptance Notice”), the Company shall issue or deliver the relevant securities to the Allottee and shall not issue or deliver such securities to any third party.</p> <p>The Company may resolve to proceed with the Additional Issuance only to the proposed third party if, and only if, the Company has not received an Acceptance Notice from the Allottee. In such case, the Company must promptly disclose the resolution of the Additional Issuance in accordance with applicable laws and regulations.</p> <p>Notwithstanding the foregoing, this provision shall not apply in any of the following cases:</p> <ol style="list-style-type: none"> <li>1) Where stock acquisition rights are issued, or common shares are issued or delivered, to the Company’s officers, employees, consultants, or advisors in accordance with a capital policy duly approved by the Board of Directors, and where the number of such shares to be issued is less than five percent (5%) of the total number of issued shares of the Company as of the execution date of the Purchase Agreement;</li> <li>2) Where the Company issues or delivers common shares upon the exercise or conversion of already issued shares (including class shares with conversion rights to common shares), stock acquisition rights, or bonds with stock acquisition rights or similar securities, which were disclosed in documents filed by the Company in accordance with applicable laws and regulations as of the execution date of the Purchase Agreement, and where such exercise or conversion is conducted in accordance with the terms and conditions set forth in such documents without any modification or amendment thereto;</li> <li>3) Any other case in which the Company and the Allottee separately agree in writing to exclude a particular act or issuance from the scope of the right of first refusal.</li> </ol> <p>In the event the Company breaches this provision and receives a demand from the Allottee, the Company shall immediately pay a penalty to EJS or to a party designated by EJS.</p>
--	--

(Note) The amount of funds to be raised is calculated by adding the total amount of the payment for the Stock Acquisition Rights and the total value of the assets to be contributed upon the exercise of the Stock Acquisition Rights (calculated based on the initial exercise price), and then subtracting the estimated total expenses associated with the issuance of the Stock Acquisition Rights. If the exercise price is revised or adjusted, the amount of funds to be raised may increase or decrease accordingly. Furthermore, the total value of the assets to be contributed upon the exercise of the Stock Acquisition Rights is based on the assumption that all Stock Acquisition Rights are exercised at the initial exercise price, and the actual amount of funds raised may vary depending on market conditions at the time of exercise. In addition, if the Stock Acquisition Rights are not exercised during the exercise period or if Stock Acquisition Rights acquired by the Company are cancelled, the amount of funds to be raised will fluctuate.